CLINICAL_TRIALS
trial_result
· 2022-07-07
Clinical Trial Update: A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma [Phase 2]
Summary
Phase 2 clinical trial update for 6MW3211 injection in relapsed/refractory lymphoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Lymphoma | Phase 2 | Status: UNKNOWN